AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01041170
Drug: THC
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01041170
Drug: Rimonobant
RxNorm normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT01041170
Drug: Rimonabant
RxNorm normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT02080312
Drug: Magnevist (gadopentetate dimeglumine)
DrugBank: Gadopentetic acid (DB00789)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00435591
Drug: Conivaptan
RxNorm normalized name: Conivaptan
DrugBank: Conivaptan (DB00872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ampoule or premix bag
Trial: NCT00210470
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 21 days of 20 mg. orally
Trial: NCT01008293
Drug: Lactulose
RxNorm normalized name: Lactulose
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 30-60 ml of lactulose per day for 2 months to ensure 2-3 soft stools.
Trial: NCT01621113
Drug: Dalfampridine
RxNorm normalized name: Dalfampridine
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalfampridine 10 mg tablet, twice-daily, for 10 weeks
Trial: NCT01614197
Drug: Temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose will be assigned at study entry. Give IV over 30 minutes on days 1 and 8.
Trial: NCT01614197
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/m2 IV over 1-2 hours daily x 5 on Days 1-5.
Trial: NCT01614197
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For Patients who are CNS1 COURSE 1: Give intrathecally to patients with CNS1 disease at the dose defined by age below on day 1 of course 1 if no other IT was given within 1 week of day 1 of course 1~* Age 1 - 1.99 give 30 mg of Cytarabine~* Age 2 - 2.99 give 50mg of Cytarabine~* Age ≥ 3 give 70 mg of Cytabine~For Patients with CNS 2 or 3 Disease COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 1 if no other IT chemotherapy given within 1 week of day 1 of course 1. Then give weekly until the patient is CNS 1 or 2 (investigator discretion). No more than 5 weekly doses to be given in cycle 1.~COURSES 2-8: Give intrathecally to patients who were CNS 2or 3 at study entry on day 1 of each course.~* 16 mg for patients age 1-1.99~* 20 mg for patients age 2-2.99~* 24 mg for patients 3-8.99 years of age~* 30 mg for patients \>9 years of age
Trial: NCT00948142
Drug: CEM-102
RxNorm normalized name: CEM-Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg BID oral tablets for 10-14 days
Trial: NCT00948142
Drug: Linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600 mg BID oral tablets
Trial: NCT00948142
Drug: CEM-102
RxNorm normalized name: CEM-Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg BID oral tablets on Day 1 followed by 600 mg BID oral tablets for a total of 10-14 days
Trial: NCT01476774
Drug: Buprenorphine Transdermal System
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control .
Trial: NCT03159143
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (28) is a semi-synthetic taxane which blocks mitosis by preventing microtubule depolymerization. It mediates its actions by binding to a different set of microtubule-associated proteins than paclitaxel. It is administered every 3 weeks as a 30 minute infusion at doses between 60 to 75 mg/m\^2.
Trial: NCT03159143
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alkylating antineoplastic agent. It is administered on day 1 of each cycle at a dose of 110 mg/m\^2
Trial: NCT00451880
Drug: XL281
RxNorm normalized name: XL281
DrugBank: XL281 (DB05190)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsules supplied as 5-, 25-, and 100-mg strengths
Trial: NCT00451880
Drug: famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose, supplied as 20-mg or 40-mg tablets
Trial: NCT00744939
Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
DrugBank: Gadopentetic acid (DB00789)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be followed for 2 years after the administration of Magnevist at the approved dose to see if symptoms consistent with NSF develop
Trial: NCT03151369
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients with the visual analog scale over 3 will receive morphine
Trial: NCT02744716
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low dose of Aspirin after operation
Trial: NCT02532400
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel: 75mg/m2, d1, q3w\*6, Epirubicin 75mg/m2, d1, q3w\*6 and Cyclophosphamide: 500mg/m2, d1, q3w\*6
Trial: NCT01649765
Drug: belimumab 10mg/kg
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: belimumab 10mg/kg IV monthly
Trial: NCT02188550
Drug: everolimus and letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented~The duration of the study will be until disease progression~Everolimus and Letrozole will be administered as noted below;~6.1.1 Dosing regimen~Dosage : Everolimus Dose: 10 Unit: mg Frequency: daily Route of administration: Orally Dosage : Letrozole Dose: 2.5 Unit: mg Frequency: daily Route of administration: Orally
Trial: NCT00927407
Drug: Malathion gel 0.5%
DrugBank: Malathion (DB00772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Malathion gel 0.5% applied to the scalp for 30 minutes
Trial: NCT00927407
Drug: Malathion lotion 0.5%
DrugBank: Malathion (DB00772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Malathion lotion 0.5% applied to scalp for 12 hours
Trial: NCT01739335
Drug: Mifepristone Oral Tablet [Korlym]
RxNorm normalized name: mifepristone Oral Tablet [Korlym]
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 Mifepristone 300 MG Oral Tablets once daily (600mg total) for 7 days
Trial: NCT00499122
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00499122
Drug: NOV 002
RxNorm normalized name: NOV-002
DrugBank: NOV-002 (DB05393)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00383136
Drug: tirofiban high-bolus dose regimen
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bolus of 25 mcg/kg of body weight, followed by 18 hours infusion of 0.15 mcg/kg/min.
Trial: NCT00383136
Drug: Abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bolus of 0.25 mg/kg of body weight, followed by 12 hours infusion of 0.125 mcg/kg per minute
Trial: NCT01217957
Drug: Ixazomib
RxNorm normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixazomib capsules
Trial: NCT01217957
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide capsules
Trial: NCT01217957
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone tablets
Trial: NCT01640054
Drug: Fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostamatinib 100mg once daily
Trial: NCT01086488
Drug: FOSCAN
DrugBank: Temoporfin (DB11630)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Patients will be randomised to one of two treatment groups. The first group of 26 patients will receive 0.1 mg/kg Foscan® at a drug-light interval of 48 hours (2 days). A single surface illumination light dose of 20 J/cm2 fluence rate of 50 mW at 652 nm will be used. The second reference group of 26 patients will be treated by intracavitary brachytherapy
Trial: NCT00118755
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130 mg/m\^2 IV on Day 1 of each 3-week cycle
Trial: NCT00118755
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 7.5 mg/kg IV on Day 1 of each 3-week cycle
Trial: NCT00118755
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m\^2 IV on Day 1 of each 2-week cycle
Trial: NCT00118755
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/kg IV on Day 1 of each 2-week cycle
Trial: NCT03005860
Drug: 2,6-Diisopropylphenol
RxNorm normalized name: 2,6-Diisopropylphenol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Propofol group, anesthesia will be induced with Propofol TCI using Schneider model to achieve a target site concentration of 4 - 6 mcg/ml. Propofol TCI to achieve BIS (Bispectral Index) between 40-60.
Trial: NCT03005860
Drug: Fluoromethyl hexafluoroisopropyl ether
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Sevoflurane group, anesthesia will be induced with 5 - 7mg/kg thiopental, maintenance with O2 with air 50:50%, sevoflurane 2-2.5 %, Further fentanyl, in increments of 1 mcg/kg - and atracurium 0.15 mg/kg, will be given as indicated by the clinical signs and hemodynamic changes.
Trial: NCT03650738
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant program: apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.
Trial: NCT03005860
Drug: Atracurium Besylate
RxNorm normalized name: Atracurium Besylate
DrugBank: Atracurium besylate (DB00732)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inj. atracurium 0.5 mg/kg for will be administered for facilitating LMA placement
Trial: NCT02486133
Drug: Prezista
RxNorm normalized name: Prezista
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: once daily
Trial: NCT02486133
Drug: Norvir
RxNorm normalized name: Norvir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: once daily
Trial: NCT02486133
Drug: Tivicay
RxNorm normalized name: Tivicay
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: once daily
Trial: NCT02486133
Drug: Truvada
RxNorm normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT02486133
Drug: Kivexa
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: once daily
Trial: NCT02486133
Drug: Descovy
RxNorm normalized name: Descovy
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: once daily
Trial: NCT04012138
Drug: Salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air) 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period.
Trial: NCT04012138
Drug: Insulin Aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients in the experimental group will receive either:~1. 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR~2. 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol.
Trial: NCT02613130
Drug: Stannous fluoride toothpaste
RxNorm normalized name: stannous fluoride Toothpaste
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02613130
Drug: Potassium nitrate toothpaste
RxNorm normalized name: potassium nitrate Toothpaste
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01130844
Drug: MMX Mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
Trial: NCT01130844
Drug: MMX Mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
Trial: NCT01130844
Drug: MMX Mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
Trial: NCT00546403
Drug: Modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive treatment with titrated dose of modafinil
Trial: NCT03057574
Drug: Follitropin Alfa
RxNorm normalized name: Follitropin Alfa
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients must be prescribed Follitropin Alfa (Gonapure®)
Trial: NCT04559880
Drug: Tranexamic Acid Injection [Cyklokapron]
RxNorm normalized name: tranexamic acid Injection [Cyklokapron]
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-procedurally, participants will receive 1 gram of intravenous tranexamic acid immediately following the polypectomy. Participants will also take oral tranexamic acid tablets (three times per day) at home for the five days following the procedure.
Trial: NCT02931071
Drug: filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: G-CSF (12 μg/Kg/12 h) 8 days.
Trial: NCT02931071
Drug: plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plerixafor 0,24 mg/kg/day after the fourth day of G-CSF, and until 5 cells CD34+/μL, max 4 doses of plerixafor
Trial: NCT03214094
Drug: Vonoprazan
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Vonoprazan tablets
Trial: NCT01248416
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01248416
Drug: Aromatase Inhibitor and Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01771328
Drug: Cortisone acetate
RxNorm normalized name: Cortisone Acetate
DrugBank: Cortisone acetate (DB01380)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take this tables two times during day according to best clinical practice of therapy of congenital adrenal hyperplasia. Usually Cortisone 25 mg 1 tbl. in the morning and Cortisone 25 1/4 tbl. in the evening. This period will take 6 months.
Trial: NCT03098420
Drug: 2mg Dexamethasone
RxNorm normalized name: dexamethasone 2 MG
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline
Trial: NCT03098420
Drug: 4mg Dexamethasone
RxNorm normalized name: dexamethasone 4 MG
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mL (4mg) of dexamethasone
Trial: NCT03098420
Drug: Ropivacaine (TAP blocks)
RxNorm normalized name: Ivy Block
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine
Trial: NCT03098420
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03098420
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03098420
Drug: Normal saline 1ml
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
Trial: NCT02521311
Drug: Clemastine
RxNorm normalized name: Clemastine
DrugBank: Clemastine (DB00283)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12mg (4mg 3x/day) clemastine for 7 days followed by 8mg clemastine (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
Trial: NCT03618823
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone will be prescribed at a dose in the range of 0.025 mg/kg to 0.10 mg/kg every four hours or as needed for adequate pain management. The total supply will be limited to seven days. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
Trial: NCT00054054
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00054054
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01131234
Drug: Cediranib Maleate
RxNorm normalized name: maleate
DrugBank: Cediranib (DB04849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01785641
Drug: ceftazidime+ciprofloxacin
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 synergistic antibiotics: ceftazidime IP + ciprofloxacin po for gram negative bacterial peritonitis
Trial: NCT01785641
Drug: ceftazidime monotherapy
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ceftazidime IP for gram negative bacterial peritonitis
Trial: NCT01785641
Drug: cefazolin monotherapy
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cefazolin IP for gram positive bacterial peritonitis
Trial: NCT00723827
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of temozolomide based on the product labeling.
Trial: NCT01674725
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet
Trial: NCT04126525
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dual HER2 blockade in the neoadjuvant setting
Trial: NCT04004208
Drug: Eylea (Aflibercept, BAY86-5321)
RxNorm normalized name: Eylea
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution in a sterile glass vial, Dose A, IVT injection.
Trial: NCT03847168
Drug: KN026
RxNorm normalized name: ANTI-HER2 BSAB KN026
DrugBank: Anbenitamab (DB18411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will be intravenously administrated with one dose of KN026 every week or every other week.
Trial: NCT01515956
Drug: BMN 110
RxNorm normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/wk over a period of approximately 4 hours every week for up to 208 weeks.
Trial: NCT00309816
Drug: sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02963103
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03374111
Drug: a Simulate Agent of Colla corii asini granule
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 g a Simulate Agent of Colla corii asini granule daily for 8 weeks
Trial: NCT02709746
Drug: Vortioxetine 10 mg/day
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
Trial: NCT03671538
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 12mg qd on day 1 to 14 of a 21-day cycle